0000899243-19-022047.txt : 20190819
0000899243-19-022047.hdr.sgml : 20190819
20190819163547
ACCESSION NUMBER: 0000899243-19-022047
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190815
FILED AS OF DATE: 20190819
DATE AS OF CHANGE: 20190819
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: New Leaf Venture Management III, L.L.C.
CENTRAL INDEX KEY: 0001625657
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38219
FILM NUMBER: 191036872
BUSINESS ADDRESS:
STREET 1: C/O NEW LEAF VENTURE PARTNERS
STREET 2: 7 TIMES SQUARE, SUITE 3502
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 646-871-6400
MAIL ADDRESS:
STREET 1: C/O NEW LEAF VENTURE PARTNERS
STREET 2: 7 TIMES SQUARE, SUITE 3502
CITY: NEW YORK
STATE: NY
ZIP: 10036
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: New Leaf Ventures III, L.P.
CENTRAL INDEX KEY: 0001625653
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38219
FILM NUMBER: 191036873
BUSINESS ADDRESS:
STREET 1: C/O NEW LEAF VENTURE PARTNERS
STREET 2: 7 TIMES SQUARE, SUITE 3502
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 646-871-6400
MAIL ADDRESS:
STREET 1: C/O NEW LEAF VENTURE PARTNERS
STREET 2: 7 TIMES SQUARE, SUITE 3502
CITY: NEW YORK
STATE: NY
ZIP: 10036
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: New Leaf Biopharma Opportunities I, L.P.
CENTRAL INDEX KEY: 0001625696
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38219
FILM NUMBER: 191036874
BUSINESS ADDRESS:
STREET 1: C/O NEW LEAF VENTURE PARTNERS
STREET 2: 7 TIMES SQUARE, SUITE 3502
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 646-871-6400
MAIL ADDRESS:
STREET 1: C/O NEW LEAF VENTURE PARTNERS
STREET 2: 7 TIMES SQUARE, SUITE 3502
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER NAME:
FORMER CONFORMED NAME: New Leaf Growth Fund I, L.P.
DATE OF NAME CHANGE: 20141117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: New Leaf Venture Associates III, L.P.
CENTRAL INDEX KEY: 0001625656
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38219
FILM NUMBER: 191036875
BUSINESS ADDRESS:
STREET 1: C/O NEW LEAF VENTURE PARTNERS
STREET 2: 7 TIMES SQUARE, SUITE 3502
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 646-871-6400
MAIL ADDRESS:
STREET 1: C/O NEW LEAF VENTURE PARTNERS
STREET 2: 7 TIMES SQUARE, SUITE 3502
CITY: NEW YORK
STATE: NY
ZIP: 10036
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: New Leaf BPO Associates I, L.P.
CENTRAL INDEX KEY: 0001625693
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38219
FILM NUMBER: 191036876
BUSINESS ADDRESS:
STREET 1: C/O NEW LEAF VENTURE PARTNERS
STREET 2: 7 TIMES SQUARE, SUITE 3502
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 646-871-6400
MAIL ADDRESS:
STREET 1: C/O NEW LEAF VENTURE PARTNERS
STREET 2: 7 TIMES SQUARE, SUITE 3502
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER NAME:
FORMER CONFORMED NAME: New Leaf Growth Associates I, L.P.
DATE OF NAME CHANGE: 20141117
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001654151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200299725
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 TOTTEN POND ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-209-6400
MAIL ADDRESS:
STREET 1: 500 TOTTEN POND ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20150928
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-08-15
1
0001654151
Deciphera Pharmaceuticals, Inc.
DCPH
0001625657
New Leaf Venture Management III, L.L.C.
C/O NEW LEAF VENTURES
420 LEXINGTON AVENUE, SUITE 408
NEW YORK
NY
10170
0
0
1
0
0001625653
New Leaf Ventures III, L.P.
C/O NEW LEAF VENTURES
420 LEXINGTON AVENUE, SUITE 408
NEW YORK
NY
10170
0
0
1
0
0001625696
New Leaf Biopharma Opportunities I, L.P.
C/O NEW LEAF VENTURES
420 LEXINGTON AVENUE, SUITE 408
NEW YORK
NY
10170
0
0
1
0
0001625656
New Leaf Venture Associates III, L.P.
C/O NEW LEAF VENTURES
420 LEXINGTON AVENUE, SUITE 408
NEW YORK
NY
10170
0
0
1
0
0001625693
New Leaf BPO Associates I, L.P.
C/O NEW LEAF VENTURES
420 LEXINGTON AVENUE, SUITE 408
NEW YORK
NY
10170
0
0
1
0
Common Stock
2019-08-15
4
S
0
71550
36.0911
D
1886282
I
See Footnote
Common Stock
2019-08-16
4
S
0
69292
36.5433
D
1816990
I
See Footnote
Common Stock
2019-08-16
4
S
0
26108
37.0148
D
1790882
I
See Footnote
Common Stock
2019-08-15
4
S
0
78450
36.0911
D
2067858
I
See Footnote
Common Stock
2019-08-16
4
S
0
75974
36.5433
D
1991884
I
See Footnote
Common Stock
2019-08-16
4
S
0
28626
37.0148
D
1963258
I
See Footnote
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
The reportable securities are owned directly by New Leaf Ventures III, L.P. ("NLV III"). New Leaf Venture Associates III, L.P. ("NLV Associates III") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. ("NLVP") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
(Continuation from footnote 2) Each of Ronald M. Hunt and Vijay K. Lathi (each, a "Member" and collectively, the "Members") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. ("Biopharma I"). New Leaf BPO Associates I, L.P. ("NLBA I") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
(Continuation from footnote 6) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
/s/ Craig Slutzkin, attorney-in-fact for New Leaf Ventures III, L.P.
2019-08-19
/s/ Craig Slutzkin, attorney-in-fact for New Leaf Biopharma Opportunities I, L.P.
2019-08-19
/s/ Craig Slutzkin, attorney-in-fact for New Leaf Venture Associates III, L.P.
2019-08-19
/s/ Craig Slutzkin, attorney-in-fact for New Leaf BPO Associates I, L.P.
2019-08-19
/s/ Craig Slutzkin, attorney-in-fact for New Leaf Venture Management III, L.L.C.
2019-08-19